NEXGARD SPECTRA 150 MG 30 MG VETERINARY

Χώρα: Ισραήλ

Γλώσσα: Αγγλικά

Πηγή: Ministry of Health

Αγόρασέ το τώρα

Δραστική ουσία:

AFOXOLANER; MILBEMYCIN OXIME

Διαθέσιμο από:

BEIT-EREZ HAVAT MILATIN LTD

Φαρμακοτεχνική μορφή:

CHEWABLE TABLETS

Σύνθεση:

AFOXOLANER 150 MG; MILBEMYCIN OXIME 30 MG

Οδός χορήγησης:

PER OS

Τρόπος διάθεσης:

Not required

Κατασκευάζεται από:

BOEHRINGER INGELHEIM VETMEDICA GMBH, GERMANY

Θεραπευτικές ενδείξεις:

For the treatment of flea and tick infestations in dogs when the concurrent prevention of heartworm disease (Dirofilaria immitis larvae), angiostrongylosis (reduction in level of immature adults (L5) and adults of Angiostrongylus vasorum) and/or treatment of gastrointestinal nematode infestations is indicated.Treatment of flea infestations (Ctenocephalides felis and C. canis) in dogs for 5 weeks.Treatment of tick infestations (Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus sanguineus) in dogs for 4 weeks.Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.Treatment of infestations with adult gastrointestinal nematodes of the following species: roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum, Ancylostoma braziliense and Ancylostoma ceylanicum) and whipworm (Trichuris vulpis).Prevention of heartworm disease (Dirofilaria immitis larvae) with monthly administration.Prevention of angiostrongylosis (by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum) with monthly administration.Treatment of demodicosis (caused by Demodex canis).Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis).

Ημερομηνία της άδειας:

2022-09-30

Φύλλο οδηγιών χρήσης

                                Page 1 of 6
VETERINARY PHYSICIAN’S PRESCRIBING INFORMATION
NEXGARD SPECTRA VETERINARY
1. TRADE NAME OF MEDICINAL PRODUCT
NEXGARD SPECTRA 9 MG / 2 MG VETERINARY – chewable tablets for dogs
2–3.5 kg
NEXGARD SPECTRA 19 MG / 4 MG VETERINARY – chewable tablets for dogs
>3.5–7.5 kg
NEXGARD SPECTRA 38 MG / 8 MG VETERINARY – chewable tablets for dogs
>7.5–15 kg
NEXGARD SPECTRA 75 MG / 15 MG VETERINARY – chewable tablets for dogs
>15–30 kg
NEXGARD SPECTRA 150 MG / 30 MG VETERINARY – chewable tablets for
dogs >30–60 kg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains:
ACTIVE SUBSTANCES:
NEXGARD SPECTRA VETERINARY
AFOXOLANER (MG)
MILBEMYCIN OXIME
(MG)
chewable tablets for dogs 2–3.5 kg
9.375 mg
1.875 mg
chewable tablets for dogs >3.5–7.5 kg
18.75 mg
3.75 mg
chewable tablets for dogs >7.5–15 kg
37.50 mg
7.50 mg
chewable tablets for dogs >15–30 kg
75.00 mg
15.00 mg
chewable tablets for dogs >30–60 kg
150.00 mg
30.00 mg
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Chewable tablets
Mottled red to reddish brown, circular shaped (tablets for dogs
2–3.5 kg) or rectangular shaped
(tablets for dogs >3.5–7.5 kg, tablets for dogs >7.5–15 kg,
tablets for dogs >15–30 kg and tablets
for dogs >30-60 kg).
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES: Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES:
-
For the treatment of flea and tick infestations in dogs when the
concurrent prevention of
heartworm disease (_Dirofilaria immitis_ larvae), angiostrongylosis
(reduction in level of immature
adults (L5) and adults of _Angiostrongylus vasorum_) and/or treatment
of gastrointestinal
nematode infestations is indicated.
-
Treatment of flea infestations (_Ctenocephalides felis_ and _C.
canis_) in dogs for 5 weeks.
-
Treatment of tick infestations (_Dermacentor reticulatus, Ixodes
ricinus, Rhipicephalus _
_sanguineus_) in dogs for 4 weeks.
-
Fleas and ticks must attach to the host and commence feeding in order
to be exposed to the
active substance.

                                
                                Διαβάστε το πλήρες έγγραφο
                                
                            

Αρχείο Π.Χ.Π.

                                Page 1 of 6
VETERINARY PHYSICIAN’S PRESCRIBING INFORMATION
NEXGARD SPECTRA VETERINARY
1. TRADE NAME OF MEDICINAL PRODUCT
NEXGARD SPECTRA 9 MG / 2 MG VETERINARY – chewable tablets for dogs
2–3.5 kg
NEXGARD SPECTRA 19 MG / 4 MG VETERINARY – chewable tablets for dogs
>3.5–7.5 kg
NEXGARD SPECTRA 38 MG / 8 MG VETERINARY – chewable tablets for dogs
>7.5–15 kg
NEXGARD SPECTRA 75 MG / 15 MG VETERINARY – chewable tablets for dogs
>15–30 kg
NEXGARD SPECTRA 150 MG / 30 MG VETERINARY – chewable tablets for
dogs >30–60 kg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains:
ACTIVE SUBSTANCES:
NEXGARD SPECTRA VETERINARY
AFOXOLANER (MG)
MILBEMYCIN OXIME
(MG)
chewable tablets for dogs 2–3.5 kg
9.375 mg
1.875 mg
chewable tablets for dogs >3.5–7.5 kg
18.75 mg
3.75 mg
chewable tablets for dogs >7.5–15 kg
37.50 mg
7.50 mg
chewable tablets for dogs >15–30 kg
75.00 mg
15.00 mg
chewable tablets for dogs >30–60 kg
150.00 mg
30.00 mg
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Chewable tablets
Mottled red to reddish brown, circular shaped (tablets for dogs
2–3.5 kg) or rectangular shaped
(tablets for dogs >3.5–7.5 kg, tablets for dogs >7.5–15 kg,
tablets for dogs >15–30 kg and tablets
for dogs >30-60 kg).
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES: Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES:
-
For the treatment of flea and tick infestations in dogs when the
concurrent prevention of
heartworm disease (_Dirofilaria immitis_ larvae), angiostrongylosis
(reduction in level of immature
adults (L5) and adults of _Angiostrongylus vasorum_) and/or treatment
of gastrointestinal
nematode infestations is indicated.
-
Treatment of flea infestations (_Ctenocephalides felis_ and _C.
canis_) in dogs for 5 weeks.
-
Treatment of tick infestations (_Dermacentor reticulatus, Ixodes
ricinus, Rhipicephalus _
_sanguineus_) in dogs for 4 weeks.
-
Fleas and ticks must attach to the host and commence feeding in order
to be exposed to the
active substance.

                                
                                Διαβάστε το πλήρες έγγραφο
                                
                            

Έγγραφα σε άλλες γλώσσες

Φύλλο οδηγιών χρήσης Φύλλο οδηγιών χρήσης Αραβικά 24-10-2023
Φύλλο οδηγιών χρήσης Φύλλο οδηγιών χρήσης Εβραϊκά 24-10-2023

Αναζήτηση ειδοποιήσεων που σχετίζονται με αυτό το προϊόν

Προβολή ιστορικού εγγράφων